APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Hormone Disorder Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Hormone Disorder Drug Industry Research Report 2026

22 December 2025134 pages

Choose your research edition.

Industry ResearchHormone Disorder Drug Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Hormone Disorder Drug Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Hormone Disorder Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hormone Disorder Drug Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Hormone Disorder Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Hormone Disorder Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Hormone Disorder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Hormone Disorder Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Hormone Disorder Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Hormone Disorder Drug include Abbott, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Sanofi, Novartis AG, Merck KGaA, Lilly, Ferring B.V and PT. Daewoong Pharmaceutical Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Hormone Disorder Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Hormone Disorder Drug Market by Company

Abbott

Teva Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Ltd

Sanofi

Novartis AG

Merck KGaA

Lilly

Ferring B.V

PT. Daewoong Pharmaceutical Company

Mayne Pharma Group Limited

Ipsen Pharma

Genentech, Inc

F. Hoffmann-La Roche Ltd

Bausch Health Companies Inc

Amneal Pharmaceutical Inc

Hormone Disorder Drug Segment by Type

Growth Hormone Stimulator

Growth Hormone Inhibitor

Hormone Disorder Drug Segment by Application

Dwarfism

Gigantism

Other

Hormone Disorder Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hormone Disorder Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hormone Disorder Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hormone Disorder Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Hormone Disorder Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Hormone Disorder Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Hormone Disorder Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Hormone Disorder Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Hormone Disorder Drug Sales (k units) of Manufacturers (2021-2026) Table 7. Global Hormone Disorder Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Hormone Disorder Drug Revenue of Manufacturers (2021-2026) Table 9. Global Hormone Disorder Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Hormone Disorder Drug Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Hormone Disorder Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Hormone Disorder Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Hormone Disorder Drug, Product Type & Application Table 14. Global Hormone Disorder Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Hormone Disorder Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Abbott Company Information Table 19. Abbott Business Overview Table 20. Abbott Hormone Disorder Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Abbott Hormone Disorder Drug Product Portfolio Table 22. Abbott Recent Developments Table 23. Teva Pharmaceutical Industries Ltd Company Information Table 24. Teva Pharmaceutical Industries Ltd Business Overview Table 25. Teva Pharmaceutical Industries Ltd Hormone Disorder Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Teva Pharmaceutical Industries Ltd Hormone Disorder Drug Product Portfolio Table 27. Teva Pharmaceutical Industries Ltd Recent Developments Table 28. Sun Pharmaceutical Industries Ltd Company Information Table 29. Sun Pharmaceutical Industries Ltd Business Overview Table 30. Sun Pharmaceutical Industries Ltd Hormone Disorder Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Sun Pharmaceutical Industries Ltd Hormone Disorder Drug Product Portfolio Table 32. Sun Pharmaceutical Industries Ltd Recent Developments Table 33. Sanofi Company Information Table 34. Sanofi Business Overview Table 35. Sanofi Hormone Disorder Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Sanofi Hormone Disorder Drug Product Portfolio Table 37. Sanofi Recent Developments Table 38. Novartis AG Company Information Table 39. Novartis AG Business Overview Table 40. Novartis AG Hormone Disorder Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Novartis AG Hormone Disorder Drug Product Portfolio Table 42. Novartis AG Recent Developments Table 43. Merck KGaA Company Information Table 44. Merck KGaA Business Overview Table 45. Merck KGaA Hormone Disorder Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Merck KGaA Hormone Disorder Drug Product Portfolio Table 47. Merck KGaA Recent Developments Table 48. Lilly Company Information Table 49. Lilly Business Overview Table 50. Lilly Hormone Disorder Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Lilly Hormone Disorder Drug Product Portfolio Table 52. Lilly Recent Developments Table 53. Ferring B.V Company Information Table 54. Ferring B.V Business Overview Table 55. Ferring B.V Hormone Disorder Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Ferring B.V Hormone Disorder Drug Product Portfolio Table 57. Ferring B.V Recent Developments Table 58. PT. Daewoong Pharmaceutical Company Company Information Table 59. PT. Daewoong Pharmaceutical Company Business Overview Table 60. PT. Daewoong Pharmaceutical Company Hormone Disorder Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. PT. Daewoong Pharmaceutical Company Hormone Disorder Drug Product Portfolio Table 62. PT. Daewoong Pharmaceutical Company Recent Developments Table 63. Mayne Pharma Group Limited Company Information Table 64. Mayne Pharma Group Limited Business Overview Table 65. Mayne Pharma Group Limited Hormone Disorder Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Mayne Pharma Group Limited Hormone Disorder Drug Product Portfolio Table 67. Mayne Pharma Group Limited Recent Developments Table 68. Ipsen Pharma Company Information Table 69. Ipsen Pharma Business Overview Table 70. Ipsen Pharma Hormone Disorder Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Ipsen Pharma Hormone Disorder Drug Product Portfolio Table 72. Ipsen Pharma Recent Developments Table 73. Genentech, Inc Company Information Table 74. Genentech, Inc Business Overview Table 75. Genentech, Inc Hormone Disorder Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Genentech, Inc Hormone Disorder Drug Product Portfolio Table 77. Genentech, Inc Recent Developments Table 78. F. Hoffmann-La Roche Ltd Company Information Table 79. F. Hoffmann-La Roche Ltd Business Overview Table 80. F. Hoffmann-La Roche Ltd Hormone Disorder Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. F. Hoffmann-La Roche Ltd Hormone Disorder Drug Product Portfolio Table 82. F. Hoffmann-La Roche Ltd Recent Developments Table 83. Bausch Health Companies Inc Company Information Table 84. Bausch Health Companies Inc Business Overview Table 85. Bausch Health Companies Inc Hormone Disorder Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Bausch Health Companies Inc Hormone Disorder Drug Product Portfolio Table 87. Bausch Health Companies Inc Recent Developments Table 88. Amneal Pharmaceutical Inc Company Information Table 89. Amneal Pharmaceutical Inc Business Overview Table 90. Amneal Pharmaceutical Inc Hormone Disorder Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Amneal Pharmaceutical Inc Hormone Disorder Drug Product Portfolio Table 92. Amneal Pharmaceutical Inc Recent Developments Table 93. Global Hormone Disorder Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 94. Global Hormone Disorder Drug Sales by Region (2021-2026) & (k units) Table 95. Global Hormone Disorder Drug Sales Market Share by Region (2021-2026) Table 96. Global Hormone Disorder Drug Sales by Region (2027-2032) & (k units) Table 97. Global Hormone Disorder Drug Sales Market Share by Region (2027-2032) Table 98. Global Hormone Disorder Drug Revenue by Region (2021-2026) & (US$ Million) Table 99. Global Hormone Disorder Drug Revenue Market Share by Region (2021-2026) Table 100. Global Hormone Disorder Drug Revenue by Region (2027-2032) & (US$ Million) Table 101. Global Hormone Disorder Drug Revenue Market Share by Region (2027-2032) Table 102. North America Hormone Disorder Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. North America Hormone Disorder Drug Sales by Country (2021-2026) & (k units) Table 104. North America Hormone Disorder Drug Sales by Country (2027-2032) & (k units) Table 105. North America Hormone Disorder Drug Revenue by Country (2021-2026) & (US$ Million) Table 106. North America Hormone Disorder Drug Revenue by Country (2027-2032) & (US$ Million) Table 107. Europe Hormone Disorder Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Europe Hormone Disorder Drug Sales by Country (2021-2026) & (k units) Table 109. Europe Hormone Disorder Drug Sales by Country (2027-2032) & (k units) Table 110. Europe Hormone Disorder Drug Revenue by Country (2021-2026) & (US$ Million) Table 111. Europe Hormone Disorder Drug Revenue by Country (2027-2032) & (US$ Million) Table 112. Asia Pacific Hormone Disorder Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Asia Pacific Hormone Disorder Drug Sales by Country (2021-2026) & (k units) Table 114. Asia Pacific Hormone Disorder Drug Sales by Country (2027-2032) & (k units) Table 115. Asia Pacific Hormone Disorder Drug Revenue by Country (2021-2026) & (US$ Million) Table 116. Asia Pacific Hormone Disorder Drug Revenue by Country (2027-2032) & (US$ Million) Table 117. South America Hormone Disorder Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. South America Hormone Disorder Drug Sales by Country (2021-2026) & (k units) Table 119. South America Hormone Disorder Drug Sales by Country (2027-2032) & (k units) Table 120. South America Hormone Disorder Drug Revenue by Country (2021-2026) & (US$ Million) Table 121. South America Hormone Disorder Drug Revenue by Country (2027-2032) & (US$ Million) Table 122. Middle East and Africa Hormone Disorder Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Middle East and Africa Hormone Disorder Drug Sales by Country (2021-2026) & (k units) Table 124. Middle East and Africa Hormone Disorder Drug Sales by Country (2027-2032) & (k units) Table 125. Middle East and Africa Hormone Disorder Drug Revenue by Country (2021-2026) & (US$ Million) Table 126. Middle East and Africa Hormone Disorder Drug Revenue by Country (2027-2032) & (US$ Million) Table 127. Global Hormone Disorder Drug Sales by Type (2021-2026) & (k units) Table 128. Global Hormone Disorder Drug Sales by Type (2027-2032) & (k units) Table 129. Global Hormone Disorder Drug Sales Market Share by Type (2021-2026) Table 130. Global Hormone Disorder Drug Sales Market Share by Type (2027-2032) Table 131. Global Hormone Disorder Drug Revenue by Type (2021-2026) & (US$ Million) Table 132. Global Hormone Disorder Drug Revenue by Type (2027-2032) & (US$ Million) Table 133. Global Hormone Disorder Drug Revenue Market Share by Type (2021-2026) Table 134. Global Hormone Disorder Drug Revenue Market Share by Type (2027-2032) Table 135. Global Hormone Disorder Drug Price by Type (2021-2026) & (US$/unit) Table 136. Global Hormone Disorder Drug Price by Type (2027-2032) & (US$/unit) Table 137. Global Hormone Disorder Drug Sales by Application (2021-2026) & (k units) Table 138. Global Hormone Disorder Drug Sales by Application (2027-2032) & (k units) Table 139. Global Hormone Disorder Drug Sales Market Share by Application (2021-2026) Table 140. Global Hormone Disorder Drug Sales Market Share by Application (2027-2032) Table 141. Global Hormone Disorder Drug Revenue by Application (2021-2026) & (US$ Million) Table 142. Global Hormone Disorder Drug Revenue by Application (2027-2032) & (US$ Million) Table 143. Global Hormone Disorder Drug Revenue Market Share by Application (2021-2026) Table 144. Global Hormone Disorder Drug Revenue Market Share by Application (2027-2032) Table 145. Global Hormone Disorder Drug Price by Application (2021-2026) & (US$/unit) Table 146. Global Hormone Disorder Drug Price by Application (2027-2032) & (US$/unit) Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Hormone Disorder Drug Distributors List Table 150. Hormone Disorder Drug Customers List Table 151. Hormone Disorder Drug Industry Trends Table 152. Hormone Disorder Drug Industry Drivers Table 153. Hormone Disorder Drug Industry Restraints Table 154. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Hormone Disorder Drug Product Image Figure 5. Global Hormone Disorder Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Hormone Disorder Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Hormone Disorder Drug Sales (2021-2032) & (k units) Figure 8. Global Hormone Disorder Drug Average Price (US$/unit) & (2021-2032) Figure 9. Growth Hormone Stimulator Product Image Figure 10. Growth Hormone Inhibitor Product Image Figure 11. Dwarfism Product Image Figure 12. Gigantism Product Image Figure 13. Other Product Image Figure 14. Global Hormone Disorder Drug Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Hormone Disorder Drug, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Hormone Disorder Drug Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Hormone Disorder Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Hormone Disorder Drug Sales by Region in 2025 Figure 20. Global Hormone Disorder Drug Revenue by Region in 2025 Figure 21. North America Hormone Disorder Drug Market Size by Country in 2025 Figure 22. North America Hormone Disorder Drug Sales Market Share by Country (2021-2032) Figure 23. North America Hormone Disorder Drug Revenue Market Share by Country (2021-2032) Figure 24. United States Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Hormone Disorder Drug Market Size by Country in 2025 Figure 28. Europe Hormone Disorder Drug Sales Market Share by Country (2021-2032) Figure 29. Europe Hormone Disorder Drug Revenue Market Share by Country (2021-2032) Figure 30. Germany Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Hormone Disorder Drug Market Size by Country in 2025 Figure 41. Asia Pacific Hormone Disorder Drug Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Hormone Disorder Drug Revenue Market Share by Country (2021-2032) Figure 43. China Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Hormone Disorder Drug Market Size by Country in 2025 Figure 52. South America Hormone Disorder Drug Sales Market Share by Country (2021-2032) Figure 53. South America Hormone Disorder Drug Revenue Market Share by Country (2021-2032) Figure 54. Brazil Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Hormone Disorder Drug Market Size by Country in 2025 Figure 58. Middle East and Africa Hormone Disorder Drug Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Hormone Disorder Drug Revenue Market Share by Country (2021-2032) Figure 60. Egypt Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries Hormone Disorder Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global Hormone Disorder Drug Sales Market Share by Type (2021-2032) Figure 66. Global Hormone Disorder Drug Revenue Market Share by Type (2021-2032) Figure 67. Global Hormone Disorder Drug Price (US$/unit) by Type (2021-2032) Figure 68. Global Hormone Disorder Drug Sales Market Share by Application (2021-2032) Figure 69. Global Hormone Disorder Drug Revenue Market Share by Application (2021-2032) Figure 70. Global Hormone Disorder Drug Price (US$/unit) by Application (2021-2032) Figure 71. Hormone Disorder Drug Value Chain Figure 72. Hormone Disorder Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Hormone Disorder Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Growth Hormone Stimulator
  • Growth Hormone Inhibitor
Applications
  • Dwarfism
  • Gigantism
  • Other
Companies covered
  • Abbott
  • Teva Pharmaceutical Industries Ltd
  • Sun Pharmaceutical Industries Ltd
  • Sanofi
  • Novartis AG
  • Merck KGaA
  • Lilly
  • Ferring B.V
  • PT. Daewoong Pharmaceutical Company
  • Mayne Pharma Group Limited
  • Ipsen Pharma
  • Genentech, Inc
  • F. Hoffmann-La Roche Ltd
  • Bausch Health Companies Inc
  • Amneal Pharmaceutical Inc

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Hormone Disorder Drug Market Size (2021-2032)
  4. 2.2.2 Global Hormone Disorder Drug Sales (2021-2032)
  5. 2.2.3 Global Hormone Disorder Drug Market Average Price (2021-2032)
  6. 2.3 Hormone Disorder Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Growth Hormone Stimulator
  9. 2.3.3 Growth Hormone Inhibitor
  10. 2.4 Hormone Disorder Drug by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Dwarfism
  13. 2.4.3 Gigantism
  14. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Hormone Disorder Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Hormone Disorder Drug Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Hormone Disorder Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Hormone Disorder Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Hormone Disorder Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Hormone Disorder Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Hormone Disorder Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Hormone Disorder Drug, Established Date
  9. 3.9 Global Hormone Disorder Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Abbott
  2. 4.1.1 Abbott Company Information
  3. 4.1.2 Abbott Business Overview
  4. 4.1.3 Abbott Hormone Disorder Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Abbott Hormone Disorder Drug Product Portfolio
  6. 4.1.5 Abbott Recent Developments
  7. 4.2 Teva Pharmaceutical Industries Ltd
  8. 4.2.1 Teva Pharmaceutical Industries Ltd Company Information
  9. 4.2.2 Teva Pharmaceutical Industries Ltd Business Overview
  10. 4.2.3 Teva Pharmaceutical Industries Ltd Hormone Disorder Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Teva Pharmaceutical Industries Ltd Hormone Disorder Drug Product Portfolio
  12. 4.2.5 Teva Pharmaceutical Industries Ltd Recent Developments
  13. 4.3 Sun Pharmaceutical Industries Ltd
  14. 4.3.1 Sun Pharmaceutical Industries Ltd Company Information
  15. 4.3.2 Sun Pharmaceutical Industries Ltd Business Overview
  16. 4.3.3 Sun Pharmaceutical Industries Ltd Hormone Disorder Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Sun Pharmaceutical Industries Ltd Hormone Disorder Drug Product Portfolio
  18. 4.3.5 Sun Pharmaceutical Industries Ltd Recent Developments
  19. 4.4 Sanofi
  20. 4.4.1 Sanofi Company Information
  21. 4.4.2 Sanofi Business Overview
  22. 4.4.3 Sanofi Hormone Disorder Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Sanofi Hormone Disorder Drug Product Portfolio
  24. 4.4.5 Sanofi Recent Developments
  25. 4.5 Novartis AG
  26. 4.5.1 Novartis AG Company Information
  27. 4.5.2 Novartis AG Business Overview
  28. 4.5.3 Novartis AG Hormone Disorder Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Novartis AG Hormone Disorder Drug Product Portfolio
  30. 4.5.5 Novartis AG Recent Developments
  31. 4.6 Merck KGaA
  32. 4.6.1 Merck KGaA Company Information
  33. 4.6.2 Merck KGaA Business Overview
  34. 4.6.3 Merck KGaA Hormone Disorder Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Merck KGaA Hormone Disorder Drug Product Portfolio
  36. 4.6.5 Merck KGaA Recent Developments
  37. 4.7 Lilly
  38. 4.7.1 Lilly Company Information
  39. 4.7.2 Lilly Business Overview
  40. 4.7.3 Lilly Hormone Disorder Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Lilly Hormone Disorder Drug Product Portfolio
  42. 4.7.5 Lilly Recent Developments
  43. 4.8 Ferring B.V
  44. 4.8.1 Ferring B.V Company Information
  45. 4.8.2 Ferring B.V Business Overview
  46. 4.8.3 Ferring B.V Hormone Disorder Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Ferring B.V Hormone Disorder Drug Product Portfolio
  48. 4.8.5 Ferring B.V Recent Developments
  49. 4.9 PT. Daewoong Pharmaceutical Company
  50. 4.9.1 PT. Daewoong Pharmaceutical Company Company Information
  51. 4.9.2 PT. Daewoong Pharmaceutical Company Business Overview
  52. 4.9.3 PT. Daewoong Pharmaceutical Company Hormone Disorder Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 PT. Daewoong Pharmaceutical Company Hormone Disorder Drug Product Portfolio
  54. 4.9.5 PT. Daewoong Pharmaceutical Company Recent Developments
  55. 4.10 Mayne Pharma Group Limited
  56. 4.10.1 Mayne Pharma Group Limited Company Information
  57. 4.10.2 Mayne Pharma Group Limited Business Overview
  58. 4.10.3 Mayne Pharma Group Limited Hormone Disorder Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Mayne Pharma Group Limited Hormone Disorder Drug Product Portfolio
  60. 4.10.5 Mayne Pharma Group Limited Recent Developments
  61. 4.11 Ipsen Pharma
  62. 4.11.1 Ipsen Pharma Company Information
  63. 4.11.2 Ipsen Pharma Business Overview
  64. 4.11.3 Ipsen Pharma Hormone Disorder Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Ipsen Pharma Hormone Disorder Drug Product Portfolio
  66. 4.11.5 Ipsen Pharma Recent Developments
  67. 4.12 Genentech, Inc
  68. 4.12.1 Genentech, Inc Company Information
  69. 4.12.2 Genentech, Inc Business Overview
  70. 4.12.3 Genentech, Inc Hormone Disorder Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Genentech, Inc Hormone Disorder Drug Product Portfolio
  72. 4.12.5 Genentech, Inc Recent Developments
  73. 4.13 F. Hoffmann-La Roche Ltd
  74. 4.13.1 F. Hoffmann-La Roche Ltd Company Information
  75. 4.13.2 F. Hoffmann-La Roche Ltd Business Overview
  76. 4.13.3 F. Hoffmann-La Roche Ltd Hormone Disorder Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 F. Hoffmann-La Roche Ltd Hormone Disorder Drug Product Portfolio
  78. 4.13.5 F. Hoffmann-La Roche Ltd Recent Developments
  79. 4.14 Bausch Health Companies Inc
  80. 4.14.1 Bausch Health Companies Inc Company Information
  81. 4.14.2 Bausch Health Companies Inc Business Overview
  82. 4.14.3 Bausch Health Companies Inc Hormone Disorder Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Bausch Health Companies Inc Hormone Disorder Drug Product Portfolio
  84. 4.14.5 Bausch Health Companies Inc Recent Developments
  85. 4.15 Amneal Pharmaceutical Inc
  86. 4.15.1 Amneal Pharmaceutical Inc Company Information
  87. 4.15.2 Amneal Pharmaceutical Inc Business Overview
  88. 4.15.3 Amneal Pharmaceutical Inc Hormone Disorder Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Amneal Pharmaceutical Inc Hormone Disorder Drug Product Portfolio
  90. 4.15.5 Amneal Pharmaceutical Inc Recent Developments
5 Global Hormone Disorder Drug Market Scenario by Region
  1. 5.1 Global Hormone Disorder Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Hormone Disorder Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Hormone Disorder Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Hormone Disorder Drug Sales by Region: 2027-2032
  5. 5.3 Global Hormone Disorder Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Hormone Disorder Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Hormone Disorder Drug Revenue by Region: 2027-2032
  8. 5.4 North America Hormone Disorder Drug Market Facts & Figures by Country
  9. 5.4.1 North America Hormone Disorder Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Hormone Disorder Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Hormone Disorder Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Hormone Disorder Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Hormone Disorder Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Hormone Disorder Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Hormone Disorder Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Hormone Disorder Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Hormone Disorder Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Hormone Disorder Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Hormone Disorder Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Hormone Disorder Drug Market Facts & Figures by Country
  41. 5.7.1 South America Hormone Disorder Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Hormone Disorder Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Hormone Disorder Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Hormone Disorder Drug Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Hormone Disorder Drug Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Hormone Disorder Drug Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Hormone Disorder Drug Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Hormone Disorder Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Hormone Disorder Drug Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Hormone Disorder Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Hormone Disorder Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Hormone Disorder Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Hormone Disorder Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Hormone Disorder Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Hormone Disorder Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Hormone Disorder Drug Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Hormone Disorder Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Hormone Disorder Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Hormone Disorder Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Hormone Disorder Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Hormone Disorder Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Hormone Disorder Drug Value Chain Analysis
  2. 8.1.1 Hormone Disorder Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Hormone Disorder Drug Production Mode & Process
  5. 8.2 Hormone Disorder Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Hormone Disorder Drug Distributors
  8. 8.2.3 Hormone Disorder Drug Customers
9 Global Hormone Disorder Drug Analyzing Market Dynamics
  1. 9.1 Hormone Disorder Drug Industry Trends
  2. 9.2 Hormone Disorder Drug Industry Drivers
  3. 9.3 Hormone Disorder Drug Industry Opportunities and Challenges
  4. 9.4 Hormone Disorder Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst